Hemostatics

• 

  Subject Areas on Research

  • A comprehensive review of topical hemostatic agents: efficacy and recommendations for use. 
  • A hemorrhage of off-label use. 
  • A multicenter, double-blind, placebo-controlled trial of aprotinin for reducing blood loss and the requirement for donor-blood transfusion in patients undergoing repeat coronary artery bypass grafting. 
  • A phase 2 prospective, randomized, double-blind trial comparing the effects of tranexamic acid with ecallantide on blood loss from high-risk cardiac surgery with cardiopulmonary bypass (CONSERV-2 Trial). 
  • Activated clotting time measurements and aprotinin studies. 
  • Activation of NADPH oxidase 1 increases intracellular calcium and migration of smooth muscle cells. 
  • Analyses of coronary graft patency after aprotinin use: results from the International Multicenter Aprotinin Graft Patency Experience (IMAGE) trial. 
  • Angiographic diagnosis and endovascular management of nonvariceal gastrointestinal hemorrhage. 
  • Anti-inflammatory strategies and hemostatic agents: old drugs, new ideas. 
  • Antiphospholipid antibodies after surgical exposure to topical bovine thrombin. 
  • Application of energy-based technologies and topical hemostatic agents in the management of surgical hemostasis. 
  • Aprotinin in primary valve replacement and reconstruction: a multicenter, double-blind, placebo-controlled trial. 
  • Aprotinin is useful as a hemostatic agent in cardiopulmonary surgery: yes. 
  • Aprotinin versus tranexamic acid: the controversy continues. 
  • Aprotinin's effect on blood product transfusion in off-pump bilateral lung transplantation. 
  • Aprotinin: a pharmacologic overview. 
  • Aprotinin: safe and effective only with the full-dose regimen. 
  • Assessment of EmboGel--a selectively dissolvable radiopaque hydrogel for embolic applications. 
  • Avoidance of primary post-tonsillectomy hemorrhage in a teaching program. 
  • Bilateral pulmonary emboli associated with intraoperative use of thrombin-based hemostatic matrix following lumbar spine interbody fusion. 
  • Bleeding and management of coagulopathy. 
  • Blood Products in the Management of Abnormal Placentation. 
  • Bovine thrombin: history, use, and risk in the surgical patient. 
  • Carotid and vertebral artery sacrifice with a combination of Onyx and coils: technical note and case series. 
  • Case 1-2008. One institution's decreasing use of aprotinin during cardiac surgery in 2006. 
  • Case 3--1999. Intraoperative coronary thrombosis in association with low-dose aprotinin therapy. 
  • Commentary: recombinant activated factor VII: the controversial conundrum regarding its off-label use. 
  • Controlled survival study of the effects of Tisseel or a combination of FloSeal and Tisseel on major vascular injury and major collecting-system injury during partial nephrectomy in a porcine model. 
  • Cost-benefit and efficacy of aprotinin compared with epsilon-aminocaproic acid in patients having repeated cardiac operations: a randomized, blinded clinical trial. 
  • Cyanoacrylate adhesives as topical hemostatic aids. II. Clinical use in seven combat casualties. 
  • Differences in bleeding phenotype and provider interventions in postmenarchal adolescents when compared to adult women with bleeding disorders and heavy menstrual bleeding. 
  • Difficult-to-control bleeding. 
  • Does body mass index impact the outcomes of tubeless percutaneous nephrolithotomy? 
  • Effectiveness of Glycerol Mono-oleate as a Biosealant. 
  • Efficacy and safety of aprotinin in cardiac surgery. 
  • Emergency portacaval shunts: is Orloff correct? 
  • Endovascular treatment of cerebral dural and pial arteriovenous fistulas. 
  • Engineering a new generation of hemostatic agents: highlights of the Scientific Session on Hemostasis at the 2013 meeting of the American Society of Hematology. 
  • Enhancement of experimental anaerobic infections by blood, hemoglobin, and hemostatic agents. 
  • Evaluation and management of postpartum hemorrhage: consensus from an international expert panel. 
  • Evaluation of the safety and efficacy of a new hemostatic powder using a quantitative surface bleeding severity scale. 
  • Evaluation of the topical hemostatic efficacy and safety of TISSEEL VH S/D fibrin sealant compared with currently licensed TISSEEL VH in patients undergoing cardiac surgery: a phase 3, randomized, double-blind clinical study. 
  • Exposure to topical bovine thrombin during surgery elicits a response against the xenogeneic carbohydrate galactose alpha1-3galactose. 
  • Fibrinogen and hemostasis: a primary hemostatic target for the management of acquired bleeding. 
  • Healthcare resource utilization in patients receiving idarucizumab for reversal of dabigatran anticoagulation due to major bleeding, urgent surgery, or procedural interventions: interim results from the RE-VERSE AD™ study. 
  • Hematologic and economic impact of aprotinin in reoperative pediatric cardiac operations. 
  • Hemostatic agents and their safety. 
  • Hemostatic agents. 
  • Hemostatic effects of antithrombin III supplementation during cardiac surgery: results of a prospective randomized investigation. 
  • Hemostatic properties of the FVIIa analog NN1731. 
  • Heterogeneity of platelet aggregation and major surface receptor expression in patients with acute myocardial infarction. 
  • High dose factor VIIa improves clot structure and stability in a model of haemophilia B. 
  • Histopathologic and immunohistochemical sequelae of bariatric embolization in a porcine model. 
  • Invited commentary. 
  • Invited letter concerning: the promotional effect of bone wax on experimental Staphylococcus aureus osteomyelitis and postoperative mediastinitis--a comparison of two electrocautery techniques on presternal soft tissues. 
  • Limitations of closing percutaneous transthoracic ventricular access ports using a commercial collagen vascular closure device. 
  • Maintaining Hemostatic Balance in Treating Disseminated Intravascular Coagulation. 
  • Maintenance of therapeutic plasma aprotinin levels during prolonged cardiopulmonary bypass using a large-dose regimen. 
  • Management of gynecologic surgery in the patient with factor XI deficiency: a review of the literature. 
  • Management of surgical hemostasis: systemic agents. 
  • Management of surgical hemostasis: topical agents. 
  • Managing clotting: a North American perspective. 
  • Massive transfusion coagulopathy. 
  • Mechanisms and monitoring of bypassing agent therapy. 
  • Middle ear packing: comparison of materials in an animal model of mucosal trauma. 
  • Multidisciplinary approach to the challenge of hemostasis. 
  • Novel delivery of oligonucleotides using a topical hydrogel tissue sealant in a murine partial nephrectomy model. 
  • Novel nuclear target for thrombin: activation of the Elk1 transcription factor leads to chemokine gene expression. 
  • Nox1 transactivation of epidermal growth factor receptor promotes N-cadherin shedding and smooth muscle cell migration. 
  • Overview of clinical efficacy and safety of pharmacologic strategies for blood conservation. 
  • Pathologic evaluation of hemostatic agents in percutaneous nephrolithotomy tracts in a porcine model. 
  • Pathophysiology of bleeding and clotting in the cardiac surgery patient: from vascular endothelium to circulatory assist device surface. 
  • Perioperative coagulation management in the intensive care unit. 
  • Perioperative hemostatic management of patients treated with vitamin K antagonists. 
  • Perioperative management of the bleeding patient. 
  • Pharmacokinetics of methanol and formate in female cynomolgus monkeys exposed to methanol vapors. 
  • Pharmacologic methods to reduce perioperative bleeding. 
  • Platelet heterogeneity: variation in coagulation complexes on platelet subpopulations. 
  • Platelet-mediated thrombolysis in patients with δ-storage pool deficiency: a thrombelastographic analysis. 
  • Predicting and preventing adverse neurologic outcomes with cardiac surgery. 
  • Product comparison model in otolaryngology: Equivalency analysis of absorbable hemostatic agents after endoscopic sinus surgery. 
  • Prohemostatic agents to prevent perioperative blood loss. 
  • Prohemostatic treatment in cardiac surgery. 
  • Prothrombin Complex Concentrates for Bleeding in the Perioperative Setting. 
  • Protocolized hemostatic factor use in major thoracic aortic surgery. 
  • Randomized evaluation of fibrinogen versus placebo in complex cardiovascular surgery: post hoc analysis and interpretation of phase III results. 
  • Randomized evaluation of fibrinogen vs placebo in complex cardiovascular surgery (REPLACE): a double-blind phase III study of haemostatic therapy. 
  • Rapid evaluation of coagulopathies after cardiopulmonary bypass in children using modified thromboelastography. 
  • Recent clinical and investigational applications of fibrin sealant in selected surgical specialties. 
  • Recent developments in topical thrombins. 
  • Recombinant activated factor VII and the anaesthetist. 
  • Recombinant activated factor VII: its mechanism of action and role in the control of hemorrhage. 
  • Relative purity of thrombin-based hemostatic agents used in surgery. 
  • Safety of aprotinin in congenital heart operations: results from a large multicenter database. 
  • Safety of aprotinin in heparinized and nonheparinized patients. 
  • Safety of recombinant activated factor VII in randomized clinical trials. 
  • Scanning electron microscopical observations of two novel hemostatic polymers. 
  • Serine 232 of the alpha(2A)-adrenergic receptor is a protein kinase C-sensitive effector coupling switch. 
  • Sonographic appearance of oxidized cellulose (Surgicel): pitfall in the diagnosis of postoperative abscess. 
  • Sonographically guided thrombin injection of iatrogenic femoral pseudoaneurysms: further experience of a single institution. 
  • Sparing of Descending Axons Rescues Interneuron Plasticity in the Lumbar Cord to Allow Adaptive Learning After Thoracic Spinal Cord Injury. 
  • Successful sonographically guided thrombin injection in an infant with a femoral artery pseudoaneurysm. 
  • Supplementary fibrinogen in the management of bleeding: re-evaluation of data from clinical trials. 
  • The Effect of Microporous Polysaccharide Hemospheres on Wound Healing and Scarring in Wild-Type and db/db Mice. 
  • The Tissue Factor Pathway and Wound Healing. 
  • The Use of Topical Hemostatic Agents in Cardiothoracic Surgery. 
  • The action of high-dose factor VIIa (FVIIa) in a cell-based model of hemostasis. 
  • The anticoagulated patient: strategies for effective blood loss management. 
  • The effect of recombinant factor VIIa on coagulopathic pigs with grade V liver injuries. 
  • The procoagulant properties of purified fibrinogen concentrate are enhanced by carbon monoxide releasing molecule-2. 
  • The role of aprotinin in a blood-conservation program. 
  • Tissue factor-activated thromboelastograms in children undergoing cardiac surgery: baseline values and comparisons. 
  • Treatment of excessive bleeding in Jehovah's Witness patients after cardiac surgery with recombinant factor VIIa (NovoSeven). 
  • Treatment of iatrogenic femoral arterial pseudoaneurysms: comparison of US-guided thrombin injection with compression repair. 
  • USE OF TANNED COLLAGEN SPONGES IN THE TREATMENT OF LIVER INJURIES. 
  • Unresectable hepatocellular carcinoma treated with radiotherapy and/or chemoembolization. 
  • Use of 1-desamino-8-D-arginine vasopressin in microsurgical reconstruction in a patient with von Willebrand's disease. 
  • Use of factor concentrates for the management of perioperative bleeding: guidance from the SSC of the ISTH. 
  • Use of fibrin sealant as a hemostatic agent after liver biopsy in swine. 
  • Use of human fibrinogen concentrate during proximal aortic reconstruction with deep hypothermic circulatory arrest. 
  • Use of the Outreach Distal Access Catheter for microcatheter stabilization during intracranial arteriovenous malformation embolization. 
  • Vessel occlusion with transcatheter electrocoagulation: initial clinical experience. 
  • Von Willebrand disease and other bleeding disorders in women: consensus on diagnosis and management from an international expert panel. 
  • [Fibrinogen and thrombin coated patch use on collagen support for lymphocele prevention after lumbar-aortic lymphadenectomy in gynecological neoplasms]. 
  • rVWF: treatment finally reaches the modern age. 
  • von Willebrand disease (VWD): evidence-based diagnosis and management guidelines, the National Heart, Lung, and Blood Institute (NHLBI) Expert Panel report (USA). 
  • von Willebrand disease in the 21st century: current approaches and new challenges. 
• 

  Keywords of People

  • Preminger, Glenn Michael, James F. Glenn, M.D. Distinguished Professor of Urology, Surgery